ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.
NexGel Inc

NexGel Inc (NXGL)

2.21
-0.075
(-3.28%)
Closed April 27 4:00PM
2.21
0.00
(0.00%)
After Hours: 5:21PM

Unlock more advanced trading tools

Join ADVFN today

Key stats and details

Current Price
2.21
Bid
1.55
Ask
2.37
Volume
7,486
2.20 Day's Range 2.28
1.40 52 Week Range 3.14
Market Cap
Previous Close
2.285
Open
2.26
Last Trade
4
@
2.1
Last Trade Time
Financial Volume
$ 16,625
VWAP
2.2208
Average Volume (3m)
22,926
Shares Outstanding
5,717,629
Dividend Yield
-
PE Ratio
-4.00
Earnings Per Share (EPS)
-0.55
Revenue
4.09M
Net Profit
-3.16M

About NexGel Inc

NexGel Inc manufactures high water content, electron beam cross-linked, aqueous polymer hydrogels, or gels, used for wound care, medical diagnostics, transdermal drug delivery, and cosmetics. The company specializes in custom gels by capitalizing on proprietary manufacturing technologies. The gels a... NexGel Inc manufactures high water content, electron beam cross-linked, aqueous polymer hydrogels, or gels, used for wound care, medical diagnostics, transdermal drug delivery, and cosmetics. The company specializes in custom gels by capitalizing on proprietary manufacturing technologies. The gels and consumer products are manufactured using proprietary and non-proprietary mixing, coating, and cross-linking technologies. The company recognizes revenue from contract manufacturing. Show more

Sector
Surgical,med Instr,apparatus
Industry
Surgical,med Instr,apparatus
Website
Headquarters
Wilmington, Delaware, USA
Founded
1970
NexGel Inc is listed in the Surgical,med Instr,apparatus sector of the NASDAQ with ticker NXGL. The last closing price for NexGel was $2.29. Over the last year, NexGel shares have traded in a share price range of $ 1.40 to $ 3.14.

NexGel currently has 5,717,629 shares outstanding. The market capitalization of NexGel is $12.64 million. NexGel has a price to earnings ratio (PE ratio) of -4.00.

NXGL Latest News

NEXGEL to Present at the Planet MicroCap Showcase: VEGAS 2024, May 1 & 2, 2024

LANGHORNE, Pa., April 18, 2024 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading provider of medical and over-the-counter (OTC) products including...

NEXGEL Reports Full Year 2023 Revenue of $4.1 Million, an Increase of 99.7% Year-Over-Year

LANGHORNE, Pa., April 01, 2024 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading provider of ultra-gentle, high-water-content hydrogel products for...

NEXGEL Reschedules Fourth Quarter and Full Year 2023 Financial Results Conference Call to Monday, April 1st at 8:30 a.m. ET Due to Holiday

LANGHORNE, Pa., March 27, 2024 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading provider of medical and over-the-counter (OTC) products including...

NEXGEL to Report Fourth Quarter and Full Year 2023 Financial Results on March 28th

Management will host a conference call at 4:30 P.M. ET on the same day LANGHORNE, Pa., March 21, 2024 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading...

NEXGEL to Present at the iAccess Alpha Best Ideas Spring Virtual Conference on March 12th

LANGHORNE, Pa., March 04, 2024 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading provider of medical and over-the-counter (OTC) products including...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10.073.271028037382.142.362.1449882.21480087CS
4-0.57-20.50359712232.782.781.98176332.24136227CS
12-0.09-3.913043478262.33.141.98229262.53908414CS
260.585361.6253.141.51196822.33837973CS
520.7248.3221476511.493.141.4375442.30891741CS
156-2.19-49.77272727274.44.661.09777082.54194635CS
260-2.19-49.77272727274.44.661.09777082.54194635CS

Market Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
BDRXBiodexa Pharmaceuticals PLC
$ 1.3254
(82.86%)
70.82M
IBRXImmunityBio Inc
$ 7.35
(43.84%)
40.28M
AGENAgenus Inc
$ 11.685
(40.78%)
3.37M
ULHUniversal Logistics Holdings Inc
$ 45.63
(38.74%)
484.22k
NIVFNewGenIvf Group Ltd
$ 1.77
(36.15%)
57.78M
MFImF International Ltd
$ 2.3153
(-77.82%)
21.23M
NWGLNature Wood Group Ltd
$ 5.05
(-70.03%)
2.48M
ICLKiClick Interactive Asia Group Ltd
$ 1.21
(-52.17%)
719.95k
NUWENewellis Inc
$ 0.1695
(-41.35%)
18.46M
SGBXSafe and Green Holdings Corporation
$ 0.1469
(-32.92%)
8.39M
PEGYPineapple Energy Inc
$ 0.065499
(26.20%)
325.57M
SQQQProShares UltraPro Short QQQ
$ 11.43
(-4.75%)
137.28M
INTCIntel Corporation
$ 31.88
(-9.20%)
119.84M
TSLATesla Inc
$ 168.29
(-1.11%)
109.84M
SOFISoFi Technologies Inc
$ 7.87
(3.69%)
88.63M

NXGL Discussion

View Posts
tdag910 tdag910 2 months ago
Winner winner chicken dinner!!
👍️0
Pinksatthehotel Pinksatthehotel 2 months ago
Looking good!
👍️0
tdag910 tdag910 5 months ago
Anybody home?
👍️0
alyck alyck 11 months ago
NXGL looking great! Solidly over $2 and volume increasing. Keep it going
👍️0
81vette 81vette 11 months ago
Ended @New 52 week high,blue sky babe!! Enjoy the weekend everyone!!
👍️0
81vette 81vette 11 months ago
contracts with pro sports teams will make brand huge,building a great company,investment in packaging plant was wise
👍️0
81vette 81vette 11 months ago
For the first quarter of 2023, revenue totaled $620 thousand and increased by $224 thousand, or 56.6%, compared to $396 thousand for the same period the year prior. The increase in overall revenues was primarily due to sales growth in both contract manufacturing and branded products. Revenue during the first quarter of 2023 includes one full month of revenue contribution from the Company’s newly formed joint venture with C.G. Laboratories.first quarter we delivered 56.6% revenue growth year-over-year, driven by increased sales in contract manufacturing and branded consumer products. We also started to see contribution in March from our new joint venture with CG Labs. During the quarter, we launched several new products and invested strategically in sales and marketing to support those launches. We are already starting to see the financial returns from these investments in the second quarter, as well as from our new JV.” “Based on the dynamic changes to our business, which include the March 1 joint venture, I feel it’s important to provide a one-time exception to our policy of not providing guidance. Based on these developments and our progress to date, we are projecting $1.0 million in revenue for the second quarter of 2023, an increase of 78.2% year-over-year. Complementing this, we had approximately $5.8 million in cash and cash equivalents at quarter-end, which gives us sufficient runway to operate and the ability to be opportunistic about further potential investments to accelerate our growth.”Acquired a 50% interest in a newly formed joint venture (“JV”), CG Converting and Packaging, LLC, with C.G. Laboratories Inc. (“CG Labs”) for its converting and packaging business.
Executed a supply agreement with a large new customer relating to a new consumer product.Launched advertising and marketing initiative, which has increased branded product sales.
👍️ 1
81vette 81vette 11 months ago
watch demand,next move up thru 52 week high,very low supply atm
👍️0
81vette 81vette 11 months ago
GOLDEN CROSS is best indicator of long bulls,follow the money is the saying
👍️0
81vette 81vette 11 months ago
eps q/q up 60%,is why moving up,big profit coming,great future $ deals,expect institutions loading long,way undervalued@ 10M mkt cap
👍️0
81vette 81vette 11 months ago
GOLDEN CROSS now,thru triple top res.,52week high>$2.00,then blue sky
👍️0
81vette 81vette 11 months ago
4M float,5M o/s,.52%short,buy vol 15X ave,not optionable,shares borrow ava. dropped 400% with pre-mkt volume,easily could go ZERO BORROW with this low float/os
👍️0

Your Recent History

Delayed Upgrade Clock